1. Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643-8.
2. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-6249s.
3. Yamada Y, Lovelock DM, Bilsky MH. A review of image-guided intensity-modulated radiotherapy for spinal tumors. Neurosurg Focus. 2003;15(5):E5.
4. Sahgal A, Ma L, Gibbs IC, Gerszten PC, Ryu S, Soltys S, et al. Spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77(2):548-53.
5. Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976). 2005;30(19):2186-91.
6. Laufer I, Rubin DG, Lis E, Cox BW, Stubblefield MD, Yamada Y, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist. 2013;18(6):744-51.
7. Barzilai O, Laufer I, Yamada Y, Lis E, McLaughlin L, Bilsky MH. Hybrid therapy for metastatic epidural spinal cord compression: separation surgery and adjuvant hypofractionated or high-dose single-fraction radiosurgery. J Neurosurg Spine. 2014;21(2):175-82.
8. Rhines LD, Goodwin CR, Hwang L, Sciubba DM, Laufer I, Yamada Y. Separation surgery for epidural spinal cord compression: a paradigm shift in the treatment of spinal metastases. J Clin Neurosci. 2015;22(4):559-63.
9. Gasbarrini A, Cappuccio M, Mirabile L, Bandiera S, Terzi S, Barbanti Bròdano G, et al. Spinal metastases: treatment evaluation algorithm. Eur Rev Med Pharmacol Sci. 2004;8:265-74.
10. Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012;159(5):499-513.
11. Sciubba DM. Current management of spinal metastases: from radiotherapy, surgery, to novel stereotactic radiosurgery options. Clin Neurosurg. 2014;61(1):17-24.
12. Klimo P Jr, Thompson CJ, Kestle JRW, Schmidt MH. A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neuro Oncol. 2005;7(1):64-77.
13. Mundy GR. Mechanisms of bone metastasis. Cancer. 1997;80(8 Suppl):1546-56.
14. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588-94.
15. Sundaresan N, DiGiacinto GV, Krol G, et al. Current and future concepts in the molecular biology of spinal metastases. Spine (Phila Pa 1976). 2009;34(22 Suppl):S14-S22.
16. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, Boer RH, et al. Denosumab compared with zoledronic acid for treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-9.
17. Ghogawala Z, Laufer I, Ehresman J, et al. The evolving role of prognostic scoring in the era of precision spine oncology. J Neurosurg Spine. 2023;38(1):123-32.
18. Batson OV. The vertebral vein system. Ann Surg. 1940;112:138-49.
19. Mont’Alverne F, Vallée JN, Cormier E, Guillevin R, Barragan H, Jean B, et al. Percutaneous vertebroplasty for metastatic involvement of the axis. AJNR Am J Neuroradiol. 2005;26(7):1641-5.
20. Tomita K, Kawahara N, Baba H, Tsuchiya H, Fujita T, Toribatake Y. Total en bloc spondylectomy: a new surgical technique for primary malignant vertebral tumors. Spine. 1997;22:324-33.
21. Silva HJS, Risso Neto MI, Pratali RR, Zuiani GR, Cavali PT, Veiga IG, et al. Avaliação da reprodutibilidade interobservadores de uma nova escala para orientação da conduta terapêutica nas metástases vertebrais – escore SINS. 2012.
22. Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, et al. A novel classification system for spinal instability in neoplastic disease. Spine. 2010;35(22):1221-9.
23. Sathiakumar C, Baré JM, Lin E, et al. Accuracy of plain radiography, computed tomography, and magnetic resonance imaging in the diagnosis of vertebral fracture. J Clin Imaging Sci. 2015;5:27.
24. Yuh WT, Zachar CK, Barloon TJ, et al. Vertebral metastases: MR assessment. Radiology. 1989;172(3):835-9.
25. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;188(6):1622-35.
26. Shah LM, Salzman KL. Imaging of spinal metastatic disease. Int J Surg Oncol. 2011;2011:769753.
27. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47(2):287-97.
28. Ziu M, Than KD, Wang AC, Etame AB, La Marca F. Current treatment paradigms for metastatic spinal disease. Neurosurg Focus. 2011;30(6):E1.
29. Shinagare AB, Ramaiya NH, Yeap BY, Van den Abbeele AD, Rosenthal DI, Hornicek FJ, et al. Metastatic spinal cord compression: a review of diagnosis, management, and prognosis. J Clin Oncol. 2011;29(22):2857-64.
30. Pratali RDR, Risso Neto MI, Zuiani GR, Cavali PTM, Pasqualini W, Veiga IG, et al. Reproducibility analysis of the stability and treatment of vertebral metastatic lesions. Coluna/Columna. 2014;13:232-4.
31. Silva HJSSD, Risso Neto MI, Pratali RDR, Zuiani GR, Cavali PTM, Veiga IG, et al. Avaliação da reprodutibilidade interobservadores de uma nova escala para orientação da conduta terapêutica nas metástases vertebrais: escore SINS (Spine Instability Neoplastic Score). Coluna/Columna. 2012;11:287-9.
32. Body JJ. Metastatic bone disease: clinical and therapeutic aspects. Bone. 2011;48(1):S107-S111.
33. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-73.
34. Sherman SI. Thyroid carcinoma. Lancet. 2003;361(9356):501-11.
35. Lis E, Bilsky MH, Pisinski L, Boland P, Healey JH, O’Malley B, et al. Percutaneous CT-guided biopsy of osseous lesions of the spine in patients with known or suspected malignancy. AJNR Am J Neuroradiol. 2004;25(9):1583-8.
36. Weber KL, McCarthy EF, Kavanagh EC, Temple HT. The role of biopsy in the diagnosis of musculoskeletal lesions: correlation with histopathologic findings and therapeutic impact. J Bone Joint Surg Am. 2007;89(6):1209-16.
37. Maclean FM, Demicco EG, Young ED, Nielsen GP, Oliveira AM, Bredella MA. Biopsy of spinal lesions: techniques, accuracy, and diagnostic yield. AJR Am J Roentgenol. 2017;209(5):1052-8.
38. Pennington Z, Ehresman J, Laufer I, Bilsky MH, Sciubba DM. Minimally invasive spine surgery for metastatic spine disease: current concepts and future directions. J Neurosurg Spine. 2021;34(2):267-75.
39. Shah AA, Paulino Pereira NR, Pedlow FX, Schwab JH. Minimally invasive surgery in the treatment of metastatic spinal disease: a review of current techniques and outcomes. J Bone Oncol. 2020;25:100321.
40. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine (Phila Pa 1976). 2001;26(3):298-306.
41. Laufer I, Iorgulescu JB, Chapman T, Lis E, Shi W, Zhang Z, et al. Local disease control for spinal metastases following “separation surgery” and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine. 2013;18(3):207-14.
42. Bilsky MH, Laufer I, Fourney DR, et al. Surgical management of spinal metastases. Oncologist. 2009;14(4):405-15.
43. Barzilai O, Laufer I, Yamada Y, Higginson DS, Schmitt AM, Lis E, et al. Integrating evidence-based medicine for treatment of spinal metastases into a decision framework: the NOMS paradigm. J Clin Oncol. 2021;39(16):1734-44.
44. Bilsky MH, Laufer I, Fourney DR, Groff M, Schmidt MH, Varga PP, et al. Reliability analysis of the epidural spinal cord compression scale. 2010;13:324-8.
45. Versteeg AL, Sahgal A, Rhines LD, et al. The role of separation surgery in the era of stereotactic body radiation therapy for metastatic spinal disease. Neurosurgery. 2020;87(3):E209-E215.
46. Loblaw DA, Mitera G, Ford M, Laperriere NJ. A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int J Radiat Oncol Biol Phys. 2012;84:312-7.
47. Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872-8.
48. Tan LA, Kasliwal MK, Nag S, et al. Role of preoperative embolization in spinal metastasis: a systematic review. J Neurosurg Spine. 2016;24(4):598-605.
49. Boriani S, Gasbarrini A, Bandiera S, Ghermandi R, Lador R. En bloc resections in the spine: the experience of 220 patients during 25 years. World Neurosurg. 2017;98:217-29.
50. Kato S, Demura S, Shinmura K, Yokogawa N, Shimizu T, Murakami H, et al. Surgical metastasectomy in the spine: a review article1. Oncologist. 2021;26:e138402.
51. Tseng CL, Eppinga W, Charest-Morin R, Soliman H, Myrehaug S, Maralani PJ, et al. Spine stereotactic body radiotherapy: indications, outcomes, and points of caution. Global Spine J. 2017;7(2):179-97.
52. Sahgal A, Whyne CM, Ma L, Larson DA, Fehlings MG. Vertebral compression fracture after spine stereotactic body radiotherapy: a systematic review and meta-analysis. Cancer. 2013;119(6):896-904.
53. Gasbarrini A, Bandiera S, Mazzetti M, et al. Minimally invasive surgery for the treatment of thoracic spine metastases: results of 139 consecutive patients. Eur Spine J. 2016;25(Suppl 1):S77-S83.
54. Landriel F, White K, Lichtenberger FP, Guiroy A, Teles A, Plasier EL, et al. CEBRT and Metastatic Spine Surgery Delphi. World Neurosurg. 2025;195:123575.
55. Enneking WF, Spanier SS, Goodman MA. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am. 1980;62(6):1027-30.
56. Stener B. Total spondylectomy in chondrosarcoma arising from the seventh thoracic vertebra. J Bone Joint Surg Br. 1971;53(2):288-95.
57. Roy-Camille R, Saillant G, Mazel CH, Monpierre H. Total vertebrectomy as treatment of malignant tumors of the spine. Chir Organi Mov. 1990;75:94-6.
58. Boriani S, Weinstein JN, Biagini R. Primary bone tumors of the spine: terminology and surgical staging. Spine. 1997;22(9):1036-44.
59. Berenson J, et al. Efficacy and safety of percutaneous vertebroplasty for cancer-related vertebral compression fractures: final results of a randomized controlled study. J Clin Oncol. 2011;29(22):3129-35.
60. Jian Yang, Qi Jia, Peng D, Wan W, Zhong N, Lou Y, et al. Surgical treatment of upper cervical spine metastases: retrospective study of 39 cases. World J Surg Oncol. 2017;15(1):21.
61. Gerszten PC, Monaco EA, Gerszten K, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. Cancer Control. 2005;12(1):79-85.
62. Fourney DR, Schomer DF, Nader R, Chlan-Fourney J, Suki D, Ahrar K, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg. 2003;98(1 Suppl):21-30.
63. Chang EL, Shiu AS, Mendel E, Mathews LA, Mahajan A, Allen PK, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine. 2007;7(2):151-160.
64. Guenette JP, Lopez MJ, Kim E, Dupuy DE. Solitary painful osseous metastases: correlation of imaging features with pain palliation after radiofrequency ablation-a multicenter American College of Radiology Imaging Network study. Radiology. 2013;268(3):907-15.
65. Wallace AN, Tomasian A, Vaswani D, Vyhmeister R, Chang RO, Jennings JW. Radiologic and clinical outcomes after vertebral augmentation with radiofrequency ablation and polymethylmethacrylate injection for painful spinal metastases. AJNR Am J Neuroradiol. 2016;37(2):405-11.
66. Cazzato RL, Garnon J, Koch G, et al. Percutaneous image-guided microwave ablation of spinal metastases: a retrospective study of safety and feasibility. Skeletal Radiol. 2015;44(10):1441-6.
67. Schneider F, Greineck F, Clausen S, Mai S, Obertacke U, Reis T, et al. Development of a novel method for intraoperative radiotherapy during kyphoplasty for spinal metastases (Kypho-IORT). Int J Radiat Oncol Biol Phys. 2011;81(4):1114-9.
68. Huisman M, et al. Photodynamic therapy in vertebral metastases: feasibility and results. Spine J. 2015.
69. Garcia PA, et al. Cardiovasc Intervent Radiol. 2014;37(2):305-16.
70. Campana LG, et al. Electrochemotherapy for bone metastases: results of a phase II clinical study. World J Surg. 2016;40(1):308-17.
71. Bertino G, et al. State of the art in electrochemotherapy: review of the literature and future perspectives. Crit Rev Oncol Hematol. 2016;107:63-77.
72. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018;29(8):1634-57.
73. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): overall survival results. Lancet Oncol. 2013;14(6):461-71.
74. Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650-63.
75. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353-66.
76. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408-18.
77. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer. JAMA Oncol. 2019;5(6):856-63.
78. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-25.
79. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-77.
80. Kim TY, Kim WB, Rhee Y, et al. Effects of therapeutic doses of 131I in patients with bone metastases from differentiated thyroid carcinoma. J Nucl Med. 2003;44(6):892-896.
81. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized trial. Lancet. 2014;384(9940):319-28.
82. Gokaslan ZL, York JE, Walsh GL, McCutcheon IE, Lang FF, Putnam Jr JB, et al. Transthoracic vertebrectomy for metastatic spinal tumors. J Neurosurg. 1998;89(4):599-609.
83. Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277-90.
84. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: a report from IMWG. J Clin Oncol. 2015;33(26):2863-9.
85. Cotten A, Dewatre F, Cortet B, Assaker R, Leblond D, Duquesnoy B, et al. Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methylmethacrylate at clinical follow-up. Radiology. 1996;200(2):525-30.
86. Berenson J, Pflugmacher R, Jarzem P, Zonder J, Schechtman K, Tillman JB, et al. Balloon kyphoplasty versus non-surgical care for vertebral compression fractures in patients with cancer. Lancet Oncol. 2011;12(3):225-35.